Your browser doesn't support javascript.
loading
Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
Rosenstock, Julio; Mathieu, Chantal; Chen, Hungta; Garcia-Sanchez, Ricardo; Saraiva, Gabriela Luporini.
  • Rosenstock, Julio; Dallas Diabetes Research Center. Dallas. US
  • Mathieu, Chantal; UZ Leuven. Leuven. BE
  • Chen, Hungta; AstraZeneca. Gaithersburg. US
  • Garcia-Sanchez, Ricardo; AstraZeneca. Gaithersburg. US
  • Saraiva, Gabriela Luporini; AstraZeneca. Gaithersburg. US
Arch. endocrinol. metab. (Online) ; 62(4): 424-430, July-Aug. 2018. tab, graf
Article in English | LILACS | ID: biblio-950077
ABSTRACT
ABSTRACT

Objective:

This analysis compared the efficacy and safety of the sodium-glucose cotransporter-2 (SGLT2) inhibitor, dapagliflozin, and the dipeptidyl peptidase-4 (DPP4) inhibitor, saxagliptin, both added on to metformin. Materials and

methods:

This was a post-hoc analysis from a double-blind, randomized, 24-week clinical trial (NCT01606007) of patients with type 2 diabetes (T2D) inadequately controlled with metformin. We compared the dapagliflozin 10 mg (n = 179) and saxagliptin 5 mg (n = 176) treatment arms.

Results:

Dapagliflozin showed significantly greater mean reductions versus saxagliptin in HbA1c (difference versus saxagliptin [95% CI] −0.32% [-0.54, −0.10]; p < 0.005), fasting plasma glucose (-0.98 [-1.42, −0.54] mmol/L; p < 0.0001), body weight (-2.39 [-3.08, −1.71] kg; p < 0.0001) and systolic blood pressure (SBP) (-3.89 [-6.15, −1.63] mmHg; p < 0.001). More dapagliflozintreated than saxagliptin-treated patients achieved the composite endpoint of HbA1c reduction ≥ 0.5%, weight loss ≥ 2 kg, SBP reduction ≥ 2 mmHg and no major/minor hypoglycemia (24% versus 7%). No major events of hypoglycemia were reported. More patients on dapagliflozin (6%) versus saxagliptin (0.6%) experienced genital infections.

Conclusion:

Dapagliflozin demonstrated greater glycemic efficacy than saxagliptin with additional benefits on weight and SBP, and the safety profile was consistent with previous studies.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Benzhydryl Compounds / Adamantane / Diabetes Mellitus, Type 2 / Dipeptides / Dipeptidyl-Peptidase IV Inhibitors / Glucosides Type of study: Controlled clinical trial Limits: Female / Humans / Male Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2018 Type: Article Affiliation country: Belgium / United States Institution/Affiliation country: AstraZeneca/US / Dallas Diabetes Research Center/US / UZ Leuven/BE

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Benzhydryl Compounds / Adamantane / Diabetes Mellitus, Type 2 / Dipeptides / Dipeptidyl-Peptidase IV Inhibitors / Glucosides Type of study: Controlled clinical trial Limits: Female / Humans / Male Language: English Journal: Arch. endocrinol. metab. (Online) Journal subject: Endocrinology / Metabolism Year: 2018 Type: Article Affiliation country: Belgium / United States Institution/Affiliation country: AstraZeneca/US / Dallas Diabetes Research Center/US / UZ Leuven/BE